

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

3 May 2024

Resignation of Directors

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, advises the resignation of Dianne Angus and Jovanka Naumoska as directors of Imagion Biosystems Limited effective immediately.

Bob Proulx, Executive Chairman said, “we would like to thank Ms Angus and Ms Naumoska for their years of service and passion to Imagion Biosystems and wish them well for their future endeavors.”

— ENDS —

About Imagion Biosystems

Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company’s lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems’ MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited.

Media & Investor Relations:

Geoff Hollis, CFO and Company Secretary
geoff.hollis@imaginationbio.com

